Document is current
Any future updates will be listed below
-
Authors
Zhao, Danhua
Zhao, Junshi
Chen, Xiaopan
Yuan, Lingfeng
Wang, Ping
Shi, Leitai
Wang, Yunpeng
Li, Jia
Zhou, Lijuan
Wu, Xiaohong
Yang, Shilong
Gao, Lidong
- License Information
-
More Information
Article History
Received: 25 July 2025
Accepted: 31 October 2025
First Online: 29 December 2025
Declarations
:
: Ethics Committee of Hunan Provincial Center for Disease Control and Prevention has approved the experiment. The ethics approval number: IRB2019007. The ethics approval date: April 23, 2019. All protocols followed were consistent with the ethical guidelines set forth by the responsible bodies for human research (at both institutional and national levels) and aligned with the Helsinki Declaration. Prior to entering the study, each participant provided written, dated informed consent.
: Not applicable.
: This study was conducted in accordance with the CONSORT guidelines, and the trial protocol was designed and implemented following the recommendations outlined in the latest version of the CONSORT statement. The manuscript has been prepared to comply with all relevant CONSORT criteria, ensuring transparent and comprehensive reporting of the trial design, methods, results, and conclusions.
: Xiaopan Chen, Lingfeng Yuan, Ping Wang, Lijuan Zhou, and Shilong Yang are employees of Anhui Zhifei Longcom Biopharmaceutical Co. Ltd., which produces the experimental vaccine evaluated in this study. The remaining authors declare no competing interests.
